Conditions: Atopic Dermatitis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 264
Healthy volunteers: no

Brief summary:
To assess the safety, tolerability and efficacy of CIM331, compared to placebo, in atopic dermatitis patients who are inadequately controlled by or intolerant to topical therapy

Detailed description:

Arms:
arm 1: Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331) arm 2: Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331) arm 3: Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331) arm 4: Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331) arm 5: Part A: Placebo Part B: nemolizumab (CIM331)

Interventions: intervention 1: nemolizumab (CIM331) intervention 2: Placebo
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: